Clinical Trials Logo

Plaque Psoriasis clinical trials

View clinical trials related to Plaque Psoriasis.

Filter by:

NCT ID: NCT02899988 Completed - Plaque Psoriasis Clinical Trials

A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Plaque Psoriasis

Start date: September 14, 2016
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to evaluate the efficacy of the study drug mirikizumab in participants with moderate to severe plaque psoriasis.

NCT ID: NCT02886702 Completed - Plaque Psoriasis Clinical Trials

A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis

Start date: September 19, 2016
Phase: Phase 3
Study type: Interventional

A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a Vehicle Control in the Treatment of Stable Plaque Psoriasis

NCT ID: NCT02881346 Completed - Plaque Psoriasis Clinical Trials

Efficacy and Tolerability of Enstilar® in Daily Practice

Start date: September 2016
Phase:
Study type: Observational

This study aims to assess how the Enstilar® aerosol foam performs in daily real-life practice with regards to effectiveness and convenience of application to psoriasis plaques on body and extremities. In addition the profiles of patients prescribed Enstilar® will be described, and preceeding, concomitant and follow-up management will be mapped. The study will be conducted in about 100 dermatology clinics all over Germany,

NCT ID: NCT02856542 Completed - Plaque Psoriasis Clinical Trials

Real-life Evaluation of the Daivobet® Gel Applicator

ASAP PSO
Start date: May 23, 2016
Phase: N/A
Study type: Observational

This study aims to describe the patient population being treated and evaluate their treatment adherence and treatment outcomes during treatment of scalp psoriasis with Daivobet® gel Applicator for 4 weeks.

NCT ID: NCT02826603 Completed - Plaque Psoriasis Clinical Trials

Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis

CLARITY
Start date: June 22, 2016
Phase: Phase 3
Study type: Interventional

Demonstrate superiority of secukinumab over ustekinumab in treatment of moderate to severe plaque psoriasis.

NCT ID: NCT02752776 Completed - Plaque Psoriasis Clinical Trials

A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis.

PROSE
Start date: March 17, 2016
Phase: Phase 4
Study type: Interventional

Study of effects of secukinumab 300 mg s.c. on quality of life (QoL) in psoriasis in patients with or without prior exposure to systemic therapy.

NCT ID: NCT02749799 Completed - Plaque Psoriasis Clinical Trials

Patient Satisfaction Following Twice Daily Dosing With DFD-01 in Subjects With Moderate Plaque Psoriasis

Start date: February 2016
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess clinical response and patient satisfaction when DFD-01 is used topically twice a day for moderate plaque psoriasis.

NCT ID: NCT02749370 Completed - Plaque Psoriasis Clinical Trials

Study to Evaluate the Efficacy of Etanercept Treatment in Adults Who Failed Therapy With Apremilast

Start date: May 18, 2016
Phase: Phase 4
Study type: Interventional

To evaluate the efficacy of etanercept in adults with moderate to severe plaque psoriasis who have failed therapy with apremilast (Otezla).

NCT ID: NCT02742441 Completed - Plaque Psoriasis Clinical Trials

A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 310)

Start date: June 2016
Phase: Phase 3
Study type: Interventional

This Phase 3 study (Study 310) has been designed to determine and compare the efficacy and safety of 122-0551 Foam and Vehicle Foam applied twice daily for two weeks in subjects with plaque psoriasis.

NCT ID: NCT02701205 Recruiting - Psoriasis Clinical Trials

Safety and Efficacy Study of Etanercept (Qiangke®) to Treat Moderate to Severe Plaque Psoriasis

Start date: January 2015
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind, multicentral clinical trial to investigate the efficacy and safety of Recombinant Human TNF Receptor-Ig Fusion Protein for Injection (Qiangke®) in the treatment of Moderate to Severe Plaque Psoriasis. The primary purpose is to assess the different maintaining treatment programme in Moderate to Severe plaque psoriasis by Qiangke®. And the second purpose is to assess the efficacy and safety of Qiangke® in Moderate to Severe Plaque Psoriasis. The trial will include 216 Moderate to Severe plaque psoriasis patients,and at the first stage they will be randomized divided into three group: full-dose of Qiangke® group, half-dose of Qiangke® group and placebo group.And the blind stage will last for 12 weeks. Then at the second stage, all patients will receive 50mg qw of Qiangke® for additional 12 weeks.